Mouse DLL4 Protein, mFc Tag
-
产品编号
KMP3945
-
别名
三角洲样典型Notch配体4, DLL4 Protein, Mouse DLL4 Protein, mFc Tag
-
规格
- 50ug
- 100ug
- 200ug
Alias | 三角洲样典型Notch配体4, DLL4 Protein, Mouse DLL4 Protein, mFc Tag |
Catalog Number | KMP3945 |
Product Description | The Mouse DLL4 Protein(KMP3945) is produced in HEK293 Cells. A DNA sequence encoding the Mouse PVR (NP_062327.2) (Met1-Pro525) is expressed with the Fc region of Mouse IgG2a at the C-terminus. |
Molecular Name | DLL4 |
Species | Mouse |
Host | HEK293 Cells |
Size | 50ug, 100ug, 200ug |
Purity | >90% as determined by SDS-PAGE |
Purification | Affinity purification |
Endotoxin | <1.0 EU/ug determined by the LAL method |
Formulation | PBS, pH7.4 |
Background | Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy. |
Storage Condition | Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles. |
Shipping Condition | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. If supplied as liquid, the proteins will be shipped with dry ice. |
Molecular Weight | 80.61 kDa |